' Intriguing ' : 9 Weeks of Trastuzumab for Breast Cancer ' Intriguing ' : 9 Weeks of Trastuzumab for Breast Cancer

Nine weeks of therapy fell short of being noninferior to 12 months for the primary outcome, but overall survival was comparable, and the shorter course is less toxic and less expensive.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news